FDA Panel Narrowly Backs Dostarlimab Trial Plans in Rectal Cancer

(MedPage Today) -- While expressing reservations, an advisory committee to the FDA backed clinical development plans for dostarlimab (Jemperli) in untreated locally advanced rectal cancer patients whose tumors are mismatch repair-deficient or carry...
Source: MedPage Today Public Health - Category: American Health Source Type: news